Abstract
Patients with primary ovarian insufficiency (POI) occasionally present with follicle growth; however, accurately predicting cycles accompanied by follicle growth is challenging. Early-stage follicles produce serum anti-Müllerian hormone (AMH), a useful marker of ovarian reserve. Therefore, serum AMH levels indicate growth of small follicles (which are difficult to detect ultrasonographically) and may predict follicle growth in patients with POI. Using an ultrasensitive enzyme-linked immunosorbent assay (ELISA) kit, we observed very low serum AMH levels in patients with POI. We further evaluated follicle growth in each patient during each cycle to determine the usefulness of measuring serum AMH levels as a predictor of follicle growth in patients with POI who receive hormone replacement therapy (HRT). We investigated 19 patients with POI in whom we analyzed 91 cycles; 14 cycles showed positive and 77 cycles showed negative results on serum AMH testing. The rate of cycles showing follicle growth in AMH-positive cycles was higher than that in AMH-negative cycles (64.3% vs. 6.5%, p = 0.0001). The median serum AMH level (7.7 pg/mL [25th and 75th percentiles 4.6 pg/mL and 22.3 pg/mL, respectively]) in AMH-positive cycles was lower than the lower limit of detection of conventional AMH ELISA kits. The positive predictive value of positive serum AMH levels for follicle growth was higher than that of follicle-stimulating hormone (< 10 mIU/mL). These results indicate that a very low level of serum AMH detected using picoAMH assays is a useful predictor of follicle growth in patients with POI receiving HRT.
Similar content being viewed by others
References
Nelson LM. Primary ovarian insufficiency. N Engl J Med. 2009;360(6):606–14.
De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. Lancet. 2010;376(9744):911–21.
Nelson LM, Anasti JN, Kimzey LM, Defensor RA, Lipetz KJ, White BJ, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab. 1994;79(5):1470–5.
Miyazaki K, Miki F, Uchida S, Masuda H, Uchida H, Maruyama T. Serum estradiol level during withdrawal bleeding as a predictive factor for intermittent ovarian function in women with primary ovarian insufficiency. Endocr J. 2015;62(1):93–9.
Surrey ES, Cedars MI. The effect of gonadotropin suppression on the induction of ovulation in premature ovarian failure patients. Fertil Steril. 1989;52(1):36–41.
Tartagni M, Cicinelli E, De Pergola G, De Salvia MA, Lavopa C, Loverro G. Effects of pretreatment with estrogens on ovarian stimulation with gonadotropins in women with premature ovarian failure: a randomized, placebo-controlled trial. Fertil Steril. 2007;87(4):858–61.
Broer SL, Broekmans FJM, Laven JSE, Fauser BCJM. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688–701.
Iwase A, Osuka S, Goto M, Murase T, Nakamura T, Takikawa S, et al. Clinical application of serum anti-Müllerian hormone as an ovarian reserve marker: a review of recent studies. J Obstet Gynaecol Res. 2018;44(6):998–1006.
Visser JA, Schipper I, Laven JSE, Themmen APN. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012;8(6):331–41.
Iwase A, Nakamura T, Kato N, Goto M, Takikawa S, Kondo M, et al. Anti-Müllerian hormone levels after laparoscopic cystectomy for endometriomas as a possible predictor for pregnancy in infertility treatments. Gynecol Endocrinol. 2016;32(4):293–7.
Iwase A, Nakamura T, Osuka S, Takikawa S, Goto M, Kikkawa F. Anti-Müllerian hormone as a marker of ovarian reserve: what have we learned, and what should we know? Reprod Med Biol. 2016;15(3):127–36.
Saito A, Iwase A, Nakamura T, Osuka S, Bayasula, Murase T, et al. Involvement of mesosalpinx in endometrioma is a possible risk factor for decrease of ovarian reserve after cystectomy: a retrospective cohort study. Reprod Biol Endocrinol. 2016;14(1):72.
Iwase A, Osuka S, Nakamura T, Kato N, Takikawa S, Goto M, et al. Usefulness of the ultrasensitive anti-Müllerian hormone assay for predicting true ovarian reserve. Reprod Sci. 2016;23(6):756–60.
Su HI, Sammel MD, Homer MV, Bui K, Haunschild C, Stanczyk FZ. Comparability of anti-Müllerian hormone levels among commercially available immunoassays. Fertil Steril. 2014;101(6):1766–72.e1.
Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant. 2013;48(3):452–8.
Check JH, Nowroozi K, Chase JS, Nazari A, Shapse D, Vaze M. Ovulation induction and pregnancies in 100 consecutive women with hypergonadotropic amenorrhea. Fertil Steril. 1990;53(5):811–6.
Li HWR, Wong BPC, Ip WK, Yeung WSB, Ho PC, Ng EHY. Comparative evaluation of three new commercial immunoassays for anti-Müllerian hormone measurement. Hum Reprod. 2016;31(12):2796–802.
Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum anti-Müllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008;90(2):395–400.
Li HWR, Wong CYG, Yeung WSB, Ho PC, Ng EHY. Serum anti-Müllerian hormone level is not altered in women using hormonal contraceptives. Contraception. 2011;83(6):582–5.
Burks HR, Ross L, Opper N, Paulson E, Stanczyk FZ, Chung K. Can highly sensitive antimüllerian hormone testing predict failed response to ovarian stimulation? Fertil Steril. 2015;104(3):643–8.
Reijnders IF, Nelen WLDM, Inthout J, Van Herwaarden AE, Braat DDM, Fleischer K. The value of anti-Müllerian hormone in low and extremely low ovarian reserve in relation to live birth after in vitro fertilization. Eur J Obstet Gynecol Reprod Biol. 2016;200:45–50.
FDA news release: FDA permits marketing of a diagnostic test to aid in the determination of menopausal status. 24 Oct 2018. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-diagnostic-test-aid-determination-menopausal-status. Accessed 15 Jan 2020.
Author information
Authors and Affiliations
Contributions
YK performed the data analysis and the writing of the manuscript. SO analyzed and interpreted the data. Bayasula measured serum levels using the picoAMH assays. Data were collected and analyzed by TM, NN, and TN. Interpretation of the data was done by MG, TK, AI, and FK. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of Interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Ethics Approval
The study was approved by the ethical committee of Nagoya University Hospital (approval reference number 422), registered as a clinical trial (UMIN000029464) on April 4, 2018. All procedures were performed according to the Declaration of Helsinki regarding human experimentation.
Statement of Informed Consent
Informed consent was obtained from all patients prior to enrollment.
Code Availability
Prism software (Prism 8; GraphPad Software, San Diego, CA USA) and EZR software (Version 1.40; Saitama Medical Center, Jichi Medical University, Saitama, Japan), the latter of which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kasahara, Y., Osuka, S., Bayasula et al. Very Low Levels of Serum Anti-Müllerian Hormone as a Possible Marker for Follicle Growth in Patients with Primary Ovarian Insufficiency Under Hormone Replacement Therapy. Reprod. Sci. 28, 31–36 (2021). https://doi.org/10.1007/s43032-020-00278-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s43032-020-00278-4